Business Wire

THERAMEX

Share
Breaking the Silence in Osteoporosis

A new international survey of 1,008 women with osteoporosis from six countries, launched on World Osteoporosis Day, reveals that while more than two-thirds (67%) of women over the age of 55 mostly understand what osteoporosis is and the potential negative impact of future fractures, 19% felt poorly informed at the time of the diagnosis.1

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211019005894/en/

The survey initiated by Theramex in cooperation with the International Osteoporosis Foundation (IOF), was conducted in Germany, France, Italy, Spain, Australia, and Brazil. It included 316 postmenopausal women over the age of 55 years and 315 premenopausal women (40-55 years) with osteoporosis (altogether 62% of the surveyed women). Of these women, osteoporosis was only diagnosed after a fracture in almost 60% of the cases. This survey highlights a gap in osteoporosis awareness, as one-fourth of the patients aged 55 years and over were not aware and did not understand the link between osteoporosis and bone fractures.1 A third (35%) of respondents said they would have been motivated to watch out for their bone health if they had known that one in three women aged over 50 will suffer a fragility fracture, but fragility fractures are preventable with the right treatment.1,2 In addition, close to 25% of postmenopausal women felt not listened to by their doctors when discussing their treatment.1

Osteoporosis is a chronic condition causing loss of bone mass and strength, resulting in fragile bones.3 It is a growing problem,3 affecting around 500 million people globally.4 Osteoporosis affects more women than men, with the risk increasing with age.5 Women are at higher risk of osteoporosis after the menopause, when the ovaries stop producing oestrogen, a hormone which has a protective effect on bones.5

Dr. Philippe Halbout, International Osteoporosis Foundation CEO said, “The impact of osteoporosis should not be underestimated. Fractures can be life-altering, causing pain, disability and loss of independence which is why it’s so important to ensure that patients are receiving the information, care and treatment they need to manage their condition and prevent or delay fractures. This survey highlights the need for improved doctor-patient communications and demonstrates the importance of education to empower women to ask for more from their care.”

Theramex CEO, Robert Stewart, commented, “Women with osteoporosis deserve support and appropriate treatment to help them continue to enjoy their lifestyles and precious moments with loved ones. We are committed to working with the osteoporosis community to provide accessible information and education about the condition, as the more women know and understand, the more they will be empowered to ask for more from their osteoporosis care, helping to reduce or eliminate the risk of fractures.”

This World Osteoporosis Day, women are being urged to #askformore from their osteoporosis care and treatment. For further information and osteoporosis resources, visit www.worldosteoporosisday.org

ENDS

NOTES TO EDITOR:

About the survey1
The online survey was conducted among 1,008 women with osteoporosis across six countries: Germany (73), France (74), Spain (122), Italy (298), Australia (54) and Brazil (387). The respondents were all female with 377 under 40, 315 aged 40-54, 201 aged 55-64, 90 aged 65-75 and 25 over 75. It should be noted that the risk of osteoporosis increases with age, despite the number of women in the younger age category in this survey. The survey was conducted between 5 – 12 July 2021 by Opinion Matters on behalf of Theramex.

About Osteoporosis
Osteoporosis remains largely underdiagnosed and undertreated, resulting in a large number of fractures.

  • It is a significant health issue – affecting ~500 million people worldwide4
  • Osteoporosis affects more women than men and risk increase with age5
  • After the menopause women start to lose bone at a faster rate, raising the risk for women who have had an early menopause or hysterectomy5
  • One in three women aged over 50 will suffer a fragility fracture2
  • Hip, spine, and wrist fractures are the most common fractures in osteoporosis and have a debilitating impact on daily activities and quality of life2
  • After a spine fracture, mortality is increased immediately after the fracture event6
  • Spine fractures can lead to back pain, loss of height, deformity, immobility, impaired quality of life (QoL), and difficulties in activities of daily living7,8,9

About the International Osteoporosis Foundation (IOF)
The International Osteoporosis Foundation is the world’s largest non-governmental organization dedicated to the prevention, diagnosis, and treatment of osteoporosis and related musculoskeletal diseases.

IOF Vision
Our vision is a world without fragility fractures, in which healthy mobility is a reality for all.

IOF Mission
To promote bone and musculoskeletal health as a worldwide priority.

About Theramex
Theramex is a leading, global speciality pharmaceutical company dedicated to women and their health. With a broad portfolio of innovative and established brands covering contraception, fertility, menopause and osteoporosis, we support women at every stage of their lives. Our commitment is to listen and understand our patients, serve their needs, and offer healthcare solutions to help improve their lives. Our vision is to be a lifetime partner for women and the healthcare professionals who treat them, by providing innovative and effective solutions that care for and support women as they advance through each stage of their lives.

References:

  1. Opinion Matters. (2021) #Askformore Osteoporosis International Survey.
  2. Cooper, C. (2019) IOF Compendium of Osteoporosis . IOF. 2nd edition.
  3. Noh, J.Y., Yang, Y. & Jung, H. (2020) Int J Mol Sci. 21 (20), 7623
  4. IOF. (n.d.) IOF website Facts and Statistics https://www.osteoporosis.foundation/facts-statistics/epidemiology-of-osteoporosis-and-fragility-fractures [Accessed 18th October 2021]
  5. IOF. (n.d.) About Osteoporosis: Risk Factors. Available from: https://www.osteoporosis.foundation/patients/about-osteoporosis/risk-factors [Accessed 18th October 2021]
  6. Johnell, O. et al. (2004) Osteoporos Int 15 (1), 38-42.
  7. Nevitt, M.C. et al. (1998) Ann Intern Med 128 (10), 793-800.
  8. Lips, P. et al (1999) Osteoporos Int 10, 150-160.
  9. Tosteson, A.N. et al (2001) Osteoporos Int 12:1042-1049.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Cegid Acquires Shine to Accelerate the Path of Becoming Europe's Leading Financial Copilot for SMBs and Accountants26.11.2025 14:00:00 CET | Press release

Transformative combination creates a powerhouse for SMBs and accountants, empowering businesses across Europe by integrating leading suites of e-invoicing, digital accounting, business accounts and payments, and HR solutions into a unified platform. Cegid, a European leader in cloud software for finance, accounting, HR, and retail software, and Shine, a fast-growing European fintech unicorn providing digital business accounts and payments, e-invoicing, accounting, and payroll software to small businesses across Europe, announced today that the companies have entered a definitive agreement to join forces to form a European champion and become a leading provider of software for businesses and their accountants. This transformational combination will create the first fully integrated, cloud-native and AI-driven financial hub for SMBs and accounting professionals in Europe – bringing together market-leading capabilities in e-invoicing, accounting, digital business accounts and payments, ta

U.S. FDA Grants Priority Review to Sonrotoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma26.11.2025 12:00:00 CET | Press release

If approved, sonrotoclax will become the first BCL2 inhibitor for R/R MCL in the U.S., addressing a high unmet need in an aggressive cancerSonrotoclax previously received Breakthrough Therapy Designation based on clinically meaningful, rapid responses in R/R MCLBeOne Medicines will present the data supporting the NDA and Priority Review for the first time at ASH 2025 BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to a New Drug Application (NDA) for sonrotoclax, a next-generation BCL2 inhibitor, for the treatment of adult patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL), following treatment with a Bruton’s tyrosine kinase (BTK) inhibitor. “Sonrotoclax is advancing with remarkable speed, from Breakthrough Therapy Designation to Priority Review, all within a short window,” said Lai Wang, Ph.D., Global Head of R&D at BeOne.

Modon Holding Announces a Strategic Investment in Wellington Lifestyle Partners, Expanding Its Global Portfolio in Luxury Lifestyle Destination Development26.11.2025 11:15:00 CET | Press release

Modon joins a consortium of investors to elevate Wellington International equestrian showgrounds and develop an ultra-luxury destination integrating residential, hospitality and sports assets in Wellington, Palm Beach County, FloridaStrengthens Modon’s global presence and enables knowledge exchange across large-scale mixed-use, hospitality and lifestyle developments Abu Dhabi-based Modon Holding P.S.C (“Modon”) today announced a strategic investment in Wellington Lifestyle Partners (“WLP”), joining a consortium of existing investors in the company. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251125937208/en/ Aerial shot of Wellington International (Photo: AETOSWire) Modon’s investment will support the long-term development of Wellington International equestrian showgrounds and deliver a landmark ultra-luxury real estate development featuring high-end residences, a boutique hotel, a commercial marketplace and a championshi

Epassi Announces Leadership Transition26.11.2025 11:00:00 CET | Press release

Nickyl Raithatha to join as Group CEOPekka Rantala to remain on Board as Non-Executive Chair Epassi Group, a European leader in digital employee benefits technology, today announced that Nickyl Raithatha will join as Chief Executive Officer. Nickyl will assume the role in 2026. Pekka Rantala, who has served as CEO since September 2019, will remain on the Board as Non-Executive Chair. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251126015983/en/ Pekka Rantala and Nickyl Raithatha Over the past six years, Epassi Group has evolved from a Nordic success story into one of Europe’s leading SaaS employee benefits and wellbeing platforms. The company has expanded both its geographic footprint as well as its product portfolio, driven by a powerful combination of strong organic growth and strategic acquisitions, with backing from TA Associates and Warburg Pincus. Today it has a presence in ten countries and a team of 1,000 people. W

Enerin raises €15 million Series A to industrialise modular high-temperature heat pumps for global industry26.11.2025 10:00:00 CET | Press release

Norway-based technology leader in industrial heat pumps, Enerin AS, has raised €15 million in an oversubscribed Series A led by Climentum Capital, The Footprint Firm, Johnson Controls and Move Energy. The investment marks Enerin’s transition from technology pioneer to serial production. Proceeds will expand commercial and manufacturing operations, and accelerate next-generation development. Johnson Controls’ participation provides strategic validation and global reach from one of the world’s leading providers of energy systems. Enerin, a technology leader in high-temperature heat pumps, has raised €15 million (NOK 180 million) in a Series A led by Climentum Capital, The Footprint Firm, Johnson Controls and Move Energy, with participation from PSV Hafnium and Momentum. “This investment marks our shift from pioneering to full industrialisation, bringing proven high-temperature technology from Norway to industries worldwide,” said Arne Høeg, Founder and CEO of Enerin. “Industrial companie

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye